>>> US Research Calls

Research Calls II
  • Upgrades:
    • ACADIA Pharmaceuticals (ACAD) upgraded to Buy from Neutral at Mizuho; tgt raised to $35
    • Bank of America (BAC) upgraded to Mkt Perform from Underperform at Keefe Bruyette; tgt raised to $30
    • Block (SQ) upgraded to Accumulate from Reduce at CLSA; tgt $57
    • Centerspace (CSR) upgraded to Buy from Neutral at Compass Point; tgt $65
    • Clorox (CLX) upgraded to Neutral from Sell at UBS; tgt raised to $132
    • Corcept Therapeutics (CORT) upgraded to Buy from Hold at Truist; tgt raised to $38
    • Dominion Energy (D) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $47
    • Entergy (ETR) upgraded to Buy from Neutral at UBS; tgt raised to $118
    • Ferrari (RACE) upgraded to Overweight from Equal Weight at Barclays
    • KeyCorp (KEY) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt raised to $15
    • Kontoor Brands (KTB) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $59
    • Park Hotels & Resorts (PK) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $19
    • Vermilion Energy (VET) upgraded to Buy from Hold at Desjardins
    • Visteon (VC) upgraded to Buy from Neutral at Citigroup; tgt $149
  • Downgrades:
    • Albemarle (ALB) downgraded to Neutral from Buy at UBS; tgt lowered to $140
    • Avient (AVNT) downgraded to Hold from Buy at Deutsche Bank; tgt lowered to $37
    • BJ's Wholesale (BJ) downgraded to Hold from Buy at Deutsche Bank; tgt lowered to $71
    • Bloomin' Brands (BLMN) downgraded to Outperform from Strong Buy at Raymond James; tgt lowered to $28
    • Cathay Bancorp (CATY) downgraded to Underweight from Neutral at Piper Sandler; tgt $31
    • CF Industries (CF) downgraded to Sector Perform from Sector Outperform at Scotiabank
    • Enersys (ENS) downgraded to Mkt Perform from Outperform at William Blair
    • EngageSmart (ESMT) downgraded to Mkt Perform from Outperform at William Blair
    • Nutrien (NTR) downgraded to Neutral from Overweight at JP Morgan; tgt lowered to $58
    • Omega Health (OHI) downgraded to Underperform from Neutral at Exane BNP Paribas
    • Paramount Global (PARA) downgraded to Underperform from Buy at BofA Securities; tgt $9
    • SolarEdge Technologies (SEDG) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $82
    • TechnipFMC (FTI) downgraded to Neutral from Outperform at Exane BNP Paribas; tgt $23.50
  • Others:
    • Bilibili (BILI) initiated with a Buy at Mizuho; tgt $18
    • Birkenstock Holding Plc (BIRK) initiated with a Buy at Citigroup; tgt $52
    • Birkenstock Holding Plc (BIRK) initiated with a Buy at Deutsche Bank; tgt $43
    • Birkenstock Holding Plc (BIRK) initiated with a Buy at Goldman; tgt $48.50
    • Birkenstock Holding Plc (BIRK) initiated with a Buy at Stifel; tgt $47
    • Birkenstock Holding Plc (BIRK) initiated with a Hold at HSBC Securities; tgt $42
    • Birkenstock Holding Plc (BIRK) initiated with a Neutral at Exane BNP Paribas; tgt $44
    • Birkenstock Holding Plc (BIRK) initiated with a Neutral at UBS; tgt $44
    • Birkenstock Holding Plc (BIRK) initiated with an Equal-Weight at Morgan Stanley; tgt $41
    • Birkenstock Holding Plc (BIRK) initiated with an Outperform at BMO Capital Markets; tgt $50
    • Birkenstock Holding Plc (BIRK) initiated with an Outperform at Robert W. Baird; tgt $48
    • Birkenstock Holding Plc (BIRK) initiated with an Outperform at William Blair
    • Birkenstock Holding Plc (BIRK) initiated with an Overweight at JP Morgan; tgt $48
    • Birkenstock Holding Plc (BIRK) initiated with an Overweight at Piper Sandler; tgt $50
    • Confluent (CFLT) initiated with an Outperform at RBC Capital Mkts; tgt $22
    • CRH Plc. (CRH) initiated with a Neutral at Goldman; tgt $58
    • Legend Biotech (LEGN) initiated with a Buy at Goldman; tgt $90.09
    • UNITIL Corporation (UTL) initiated with a Neutral at Guggenheim
    • WK Kellogg Co (KLG) initiated with an Underweight at Barclays; tgt $11
    • World Kinect Corporation (WKC) initiated with an Equal-Weight at Morgan Stanley; tgt $24
    • WPP plc (WPP) resumed with an Equal-Weight at Morgan Stanley

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • KRYS +8.8%, FRPT +7.8%, AMG +4.7%, KNF +3.8%, AL +3.1%, BNTX +2.7%, UUUU +2.6%, ERJ +2.2%, CEG +2%, ACRS +2%, KOS +1.9%, HGV +1.3%, VVX +1.1%
Other news:
  • CLDX +26.1% (files mixed shelf securities offering; also Presents Positive Data from Prurigo Nodularis Phase 1b Study and topline results from barzolvolimab Phase 2 Study)
  • CRSP +5.5% (Announces Preclinical Data at the American Heart Association)
  • BTAI +5.2% (announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder)
  • FSR +2.9% (promotes David King as its new Chief Technology Officer)
  • LUMN +2.7% (CEO bought 1000000 shares at $0.97 worth ~$970K)
  • VIR +2.6% (files mixed securities shelf offering)
  • HALO +2.6% (Halozyme Therapeutics and Acumen Pharmaceuticals (ABOS) announce global collaboration and non-exclusive license agreement for the ENHANZE Technology in Alzheimer's Disease)
  • TCRX +2.2% (Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting)
  • HUT +2.1% (reports Oct metrics)
  • RGNX +2% (Presents Positive One Year Data from Phase II ALTITUDE Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery)
  • CABA +1.9% (FDA clears CABA-201 a 4-1BB-containing fully human CD19-CAR T cell investigational therapy)
  • DNA +1.8% (Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens)
  • REPL +1.5% (Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy)
  • ALGN +1.2% (planning to repurchase $100 million of Align's common stock through open market repurchases under Align's $1.0 billion stock repurchase program)
Analyst comments:
  • ACAD +3.5% (upgraded to Buy from Neutral at Mizuho)
  • KEY +2% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
  • VC +1.4% (upgraded to Buy from Neutral at Citigroup)
  • SQ +1.3% (upgraded to Accumulate from Reduce at CLSA)
  • CLX +1.2% (upgraded to Neutral from Sell at UBS)
  • VET +1% (upgraded to Buy from Hold at Desjardins)

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • TGLS -18.3%, DISH -6.6%, THS -0.7%
Other news:
  • KOD -8.1% (reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study)
  • ALPN -4.7% (commenced an underwritten public offering of $150 million of shares pursuant to its existing shelf registration statement)
  • MLTX -4.5% (announces landmark Phase 2 results for Nanobody sonelokimab)
  • PAC -2.5% (reports October traffic increased 4.7% yr/yr)
  • OVID -2% (files $250 mln mixed shelf securities offering)
  • APLS -1.9% (reports SYFOVRE (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy)
  • TRMB -1.2% (Trimble's Viewpoint Spectrum and Viewpoint Vista construction enterprise resource planning (ERP) software now includes Automatic Invoicing capability)
  • LGIH -1.1% (Oct closings)
  • CRBG -1.1% (AIG announces launch of secondary offering of Corebridge Financial (CRBG) common stock)
Analyst comments:
  • ALB -1.1% (downgraded to Neutral from Buy at UBS)

>>> Embraer SA reports Q3 (Sep) results, misses on revs; reaffirms outlook (15.1

Embraer SA reports Q3 (Sep) results, misses on revs; reaffirms outlook (15.15)
  • Reports Q3 (Sep) earnings of $0.38 per share, may not be comparable to the two analyst estimate of $0.24; revenues rose 38.1% year/year to $1.28 bln vs the $1.33 bln FactSet Consensus.
    • Firm order backlog ended 3Q23 at $17.8 billion, the highest level in one year, driven by higher sales in Commercial Aviation. Commercial Aviation backlog rose from $8 billion to $8.6 billion compared to 2Q23, with 42 aircraft sold in 2023. Services & Support reached $2.8 billion in the quarter, the highest volume ever recorded in the business unit. Executive Aviation strong backlog at $4.3 billion highlights its sustained demand backlog.
  • Operational and financial guidance for 2023 remains unchanged

>>> Constellation Energy beats by $0.78, misses on revs (117.07)

Constellation Energy beats by $0.78, misses on revs (117.07)
  • Reports Q3 (Sep) earnings of $2.26 per share, $0.78 better than the FactSet Consensus of $1.48; revenues rose 1.0% year/year to $6.11 bln vs the $7.01 bln FactSet Consensus.
  • Raising guidance range for full year 2023 Adjusted EBITDA (non-GAAP) to $3,800 million to $4,000 million.
  • "Our continued strong performance this quarter is the result of pairing the nation's largest clean energy fleet with an unmatched commercial business, allowing us to produce affordable and reliable carbon-free energy when and where American families and businesses need it," said Joe Dominguez, president and CEO of Constellation. "This combination of businesses is the fundamental strength of our strategy. It allows us to help customers like Microsoft and ComEd manage their energy costs in a volatile market, while also lowering their carbon emissions with clean energy matched to their use in every hour of every day. We continue to execute our growth strategy, closing on the South Texas Project transaction ahead of schedule and moving forward with $1.5 billion in growth spending on equipment to increase the output of our nuclear plants, wind repowering and pursuit of a nuclear-powered clean hydrogen facility as part of a multi-state hub."
  • "Our generation fleet performed at peak levels during a summer of record heat, while our commercial business continued to win new business and realize higher margins," said Dan Eggers, executive vice president and chief financial officer. "Our gross margin outlook for 2023 is now $850 million higher than our expectations at the start of the year and our outlook for 2024 has increased. Based on current market conditions and the continued strength of our operations, we are raising 2023 adjusted EBITDA guidance to a $3.9 billion mid-point and narrowing the range to $3.8 billion to $4 billion."

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • CLDX +14.7%, PHIN +7%, PRME +6.4%, CRSP +6.2%, VIR +3.8%, HUT +3.8%, LUMN +3.6%, FSR +3.3%, KOS +2.4%, FRPT +2.1%, RGNX +2%, UUUU +1.8%, OLK +1.4%, TRMB +1.4%, ALGN +1.2%
  • Gapping down:
    • KOD -9.3%, DISH -7.8%, ALPN -4.3%, TSE -3%, PAC -2.5%, MLTX -2.4%, SRRK -2.3%, OVID -2%, VERA -2%, APLS -1.3%, LGIH -1.1%

FT : Lidl owner co-leads $500mn deal to fuel German AI start-up

Lidl owner co-leads $500mn deal to fuel German AI start-up
Investment in Aleph Alpha involves equity injection, research grants and commitments to joint business development

The owners of the Lidl supermarket chain are among those investing more than $500mn in German artificial intelligence start-up Aleph Alpha, as it seeks to capitalise on a global rush into the sector.

Schwarz Group, which controls Lidl and is building out a new IT division, is co-leading the deal alongside an AI hub based in the south-west German city of Heilbronn that was jointly set up by a foundation established by Dieter Schwarz, the Lidl founder.

Other investors include the venture capital unit of Bosch, Europe’s largest car parts supplier, according to an Aleph Alpha statement.

Founded in 2019, Aleph Alpha is among the most prominent European start-ups that focus on generative AI, the software that can create sophisticated text, imagery or computer code that mimics human ability.

But the German start-up may struggle to break through in an increasingly crowded generative AI market, with better funded competitors such as Microsoft-backed OpenAI, Google and Facebook parent Meta all investing heavily in the space.

Aleph Alpha, which has about 70 employees, aims to distinguish itself by offering data protection, security and transparent software to clients including in sensitive sectors such as law enforcement and healthcare. It has already raised about €28mn.

“We need to make sure we have a hand on the wheel of how the future will turn out,” Aleph Alpha chief executive Jonas Andrulis told the Financial Times. The company’s clients “have full sovereignty over what’s going on”.

Roughly a quarter of the funding comes via an equity investment, with the remainder composed of research grants and commitments for joint business development that will not dilute shareholders, said people familiar with the deal. They added that Aleph Alpha’s equity would be valued at roughly €500mn in the transaction.

The company did not disclose its valuation.

Schwarz Group, an unlisted and family-controlled giant with €154bn in annual revenue and 575,000 staff worldwide, is best known for its Lidl discount supermarkets. But it has also branched out into food manufacturing, recycling and IT services. In September, it pooled its cloud and cyber security offerings into a standalone unit, Schwarz Digits, which services the rest of Schwarz operations as well as external clients.

Dieter Schwarz this year backed the Heilbronn hub, Innovation Park Artificial Intelligence, which is also funded by the state of Baden-Württemberg and aims to become Europe’s largest AI cluster.

“Cash is necessary, but not sufficient,” said Andre Retterath, a partner at the venture capital firm Earlybird and an Aleph Alpha board member. The partnerships will give the company “access to compute, access to talent, and distribution into the market”, he said. Earlybird led a 2021 funding round for the German start-up.

Aleph Alpha wants to accelerate its expansion as it sees a window over the coming 12 to 24 months during which companies will test and select which AI software they plan to use.

While some of Aleph Alpha’s competitors have developed close corporate relationships with the largest technology groups, the company stressed that it is independent.

Other investors in the consortium include IT business Hewlett Packard Enterprise and German software company SAP, as well as VC group Burda Principal Investments, and existing backers, the statement said. The company has been previously supported by VC groups UVC Partners, LEA Partners, 468 Capital, Cavalry Ventures and Lakestar.

FT : Telecom Italia’s KKR deal sparks threat of legal action by Vivendi

Telecom Italia’s KKR deal sparks threat of legal action by Vivendi
Largest shareholder ‘deeply regrets’ acceptance of private equity’s firm offer of up to €22bn for fixed-line network

Telecom Italia is being threatened with legal action from Vivendi, its single largest shareholder, after accepting KKR’s offer of up to €22bn for the telecoms group’s fixed-line phone and internet network.

Telecom Italia’s board of directors approved the sale on Sunday in a majority vote. It comes two years after the private equity firm’s first €33bn takeover offer which envisaged taking the company private.

In response, the French media conglomerate said in a statement that it “deeply regrets” the board accepting the offer without requesting a “vote from its shareholders”. It added that it will “use any legal means at its disposal to challenge this decision”.

However, the board said the decision to accept the offer was of its “exclusive competence”. It also mandated chief executive Pietro Labriola to sign contracts and verify the possibility of receiving a binding offer at a higher value for its submarine network Sparkle.

Under the deal, expected to close next summer, Telecom Italia said it will reduce its €26bn debt pile by around €14bn. The junk-rated company also said the transaction will reduce regulatory constraints in its domestic market, which have hindered its growth, and will help it to maintain strategic flexibility.

Telecom Italia hopes the plan will improve the company’s share price but it has long been opposed by Vivendi. The conglomerate, owned by the Bolloré family, holds a 23.75 per cent stake and more than 17 per cent of Telecom Italia’s voting rights.

Shares in Telecom Italia were down 3.6 per cent to €0.25 in morning trading on Monday. Shares in Vivendi were down 0.4 per cent to €8.63.

The French group has invested more than €4bn in building the stake over the past eight years and has had to write down its investment twice as Telecom Italia’s valuation has fallen amid high debt, multiple management overhauls, lower margins and increased domestic competition. 

Vivendi has previously rejected plans to separate the network from the group’s services business, saying Telecom Italia had undervalued it. 

Labriola was put in place, with Vivendi’s backing, two years ago after his predecessor was ousted over KKR’s first offer. He has since become the main sponsor of KKR’s plan to split and turn round the business.

“Two years of hard work with our heads down wrap up with a historic decision which will see the creation of two separate companies with entirely new development perspectives,” he said in a statement.

The Italian government, which can veto deals involving telecommunications infrastructure, greenlighted the deal last month. Rome’s department of the Treasury plans to spend more than €2bn in taking a 20 per cent stake in the network company, alongside KKR, to oversee an asset which it deems strategic.

>>> Europe : Brokers Upgrades & Downgrades - 6th of November 2023 V3(++)

>>> Up
* Acadia Pharma Raised to Buy at Mizuho Securities; PT $35
* Apple Raised to Accumulate at Phillip Secs; PT $194
* Bank of America Raised to Market Perform at KBW; PT $30
* BMW Raised to Outperform at Bernstein (++)
* CRH Raised to Neutral at Goldman; PT $58
* Dino Polska Raised to Neutral at JPMorgan; PT 450 zloty
* Dominion Energy Raised to Overweight at Barclays; PT $47
* EDP Raised to Outperform at BNPP Exane
* EDP Renovaveis Raised to Sector Perform at RBC; PT 18 euros
* Exel Composites Raised to Reduce at Inderes; PT 2.50 euros
* Ferrari Raised to Overweight at Barclays; PT $375.83
* Kontoor Brands Raised to Overweight at Barclays; PT $59
* Maersk Raised to Hold at SEB Equities; PT 10,100 kroner (++)
* Rentokil Raised to Buy at HSBC; PT 495 pence
* Siemens Raised to Outperform at Oddo BHF (+)
* Stadler Rail Raised to Neutral at Oddo BHF; PT 31 Swiss francs
* Telefonica Deutschland Raised to Buy at M.M. Warburg (+)
* Umicore Raised to Equal-Weight at Barclays; PT 29 euros

>>> Down
* Acerinox Cut to Add at AlphaValue/Baader
* Anima Holding Cut to Hold at Kepler Cheuvreux; PT 4.10 euros (+)
* Albemarle PT Cut to $90 from $155 at Morgan Stanley
* BCP Cut to Neutral at Mediobanca SpA; PT 36 euro cents
* Citycon Cut to Sell at DNB Markets; PT 4 euros (++)
* Evotec SE Cut to Sector Perform at RBC
* Genus Cut to Hold at Investec; PT 2,317 pence (+)
* Grieg Seafood Cut to Hold at Carnegie; PT 82 kroner (++)
* Heidelberg Materials Cut to Neutral at UBS; PT 74 euros (+)
* Johnson Matthey PT Cut to 2,380 pence at Panmure Gordon (++)
* K+S Cut to Sell at UBS (+)
* Kahoot Cut to Equal-Weight at Morgan Stanley; PT 35 kroner
* Neoen Cut to Hold at Portzamparc; PT 30 euros
* Next Cut to Sector Perform at RBC; PT 7,700 pence
* Nutrien Cut to Neutral at JPMorgan; PT C$79.18
* Oerlikon Cut to Sector Perform at RBC
* SolarEdge Cut to Hold at HSBC; PT $80
* SpareBank 1 Sorost-Norge Cut to Neutral at SpareBank
* TechnipFMC Cut to Neutral at BNPP Exane; PT $23.50 (++)
* Vonovia Cut to Sell at Bankhaus Metzler; PT 21 euros (+)

>>> Initiation
* Birkenstock Holding Rated New Overweight at Piper Sandler (++)
* Birkenstock Holding Rated New Outperform at Baird; PT $48
* Birkenstock Holding Rated New Buy at Goldman; PT $48.50
* Birkenstock Holding Rated New Overweight at JPMorgan; PT $48
* Birkenstock Holding Rated New Equal-Weight at Morgan Stanley
* Birkenstock Holding Rated New Outperform at BMO; PT $50
* Birkenstock Holding Rated New Buy at Jefferies; PT $50
* Birkenstock Holding Rated New Buy at Williams Trading; PT $55
* Birkenstock Holding Rated New Buy at Citi; PT $52
* Birkenstock Holding Rated New Hold at HSBC; PT $42
* Birkenstock Holding Rated New Buy at Stifel; PT $47
* Cytokinetics Rated New Outperform at Baptista Research
* Fashionette Reinstated Buy at Hauck & Aufhaeuser; PT 18 euros (+)
* Getinge Reinstated Buy at Danske Bank Markets; PT 300 kronor (++)
* Getinge Re-Initiated Buy at Carnegie; PT 300 kronor (++)
* JD Sports Rated New Buy at Citi; PT 220 pence
* Marley Spoon Group Rated New Buy at M.M. Warburg; PT 10.50 euros (+)
* Omer Rated New Buy at TP ICAP Midcap; PT 4.40 euros (+)
* Puma Rated New Neutral at Citi; PT 58 euros
* Sandoz Group Rated New Buy at Stifel; PT 40 Swiss francs
* VAT Rated New Hold at Jefferies; PT 370 Swiss francs
* World Kinect Corp Rated New Equal-Weight at Morgan Stanley

>>> Call
* Anima Holding Declines as Kepler Downgrades on Limited Upside (++)
* BMW Gains; Bernstein Sees Outperformance Versus Peers, Upgrades (++)
* Entain Gains After Jefferies Raises PT on 2025 Estimate Upgrade (++)
* Evotec Downgraded at RBC on Significant Near-Term Uncertainty
* Evotec Drops as RBC Cuts on Major Near-Term Uncertainty (++)
* Ferrari Gains; Barclays Upgrades as Pricing, Orders ‘Bode Well’ (++)
* Heidelberg Materials Gets A Downgrade at UBS On M&A Concerns (+)
* JD Sports Gains as Citi Initiates at Buy; Rates Puma Neutral (++)
* K+S Cut to Sell at UBS With Street-Low PT on Potash Prices (+)
* Morgan Stanley’s Wilson Says Stock Gains Are a Bear Market Rally (+)
* Next Cut, Dunelm Raised at RBC; AB Foods Among Top Retail Picks
* Oerlikon Cut to Sector Perform at RBC After ‘Sobering’ Results
* PostNL Parcel Volume Recovery Slower Than Expected: Jefferies (+)
* Stadler Rail Gains on Oddo Lift; Valuation Offers Entry Point (++)
* VAT Rated New Hold at Jefferies, Near-Term Outlook Priced In